Novartis Kisqali® prolonged PFS benefit for pre- and perimenopausal patients with aggressive HR+/HER2− metastatic breast cancer compared to chemotherapy

(marketscreener.com) RIGHT Choice Phase II trial is the first randomized study in patients with aggressive HR+/HER2− metastatic breast cancer , including visceral crisis, comparing a CDK4/6 inhibitor plus endocrine therapy versus combination chemotherapy 1Kisqali plus ET demonstrated a statistically significant progression-free survival benefit of one year...https://www.marketscreener.com/quote/stock/NOVARTIS-AG-9364983/news/Novartis-Kisqali-prolonged-PFS-benefit-for-pre-and-perimenopausal-patients-with-aggressive-HR-HER-42489166/?utm_medium=RSS&utm_content=20221206